Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists (Q26823085)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25338737%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

review article

3 references

27 October 2020

4 February 2021

Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists (English)

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25338737%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

main subject

cardiovascular disease

8 references

13 March 2019

14 March 2019

24 March 2019

17 June 2019

31 July 2019

10 October 2019

15 December 2019

27 October 2020

cell surface receptor

1 reference

31 July 2019

5 references

31 July 2019

10 October 2019

15 December 2019

27 October 2020

4 February 2021

1 reference

10 October 2019

1 reference

15 December 2019

anti-diabetic medication

1 reference

27 October 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25338737%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Francisco Kerr Saraiva

series ordinal

1

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25338737%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

language of work or name

1 reference

22 October 2014

11 references

13 March 2019

14 March 2019

24 March 2019

17 June 2019

31 July 2019

10 October 2019

15 December 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25338737%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

27 October 2020

4 February 2021

Cardiovascular Diabetology

11 references

13 March 2019

14 March 2019

24 March 2019

17 June 2019

31 July 2019

10 October 2019

15 December 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25338737%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

27 October 2020

4 February 2021

13

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25338737%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

142

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25338737%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution

21 February 2020

copyright license

9 references

13 March 2019

14 March 2019

24 March 2019

17 June 2019

31 July 2019

10 October 2019

15 December 2019

27 October 2020

4 February 2021

0 references

on focus list of Wikimedia project

ScienceSource

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/s12933-014-0142-7

0 references

cites work

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Biology of incretins: GLP-1 and GIP

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Protective role of retinoid X receptor in H9c2 cardiomyocytes from hypoxia/reoxygenation injury in rats

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

The role of glucagon on type 2 diabetes at a glance.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Cardiovascular actions of incretin-based therapies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Glucose-stimulated insulin secretion: A newer perspective

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Cardioprotective effects of exenatide against oxidative stress-induced injury

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protection

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Glucagon-like peptide-1 receptor-mediated endosomal cAMP generation promotes glucose-stimulated insulin secretion in pancreatic β-cells.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Glucagon-like peptide 1 and appetite

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Predicted structure of agonist-bound glucagon-like peptide 1 receptor, a class B G protein-coupled receptor

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Pleiotropic effects of incretins

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Myocardial AKT: the omnipresent nexus

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagon-like peptide 1 in diabetes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Glucagon-like peptide-1 increases beta-cell glucose competence and proliferation by translational induction of insulin-like growth factor-1 receptor expression

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Hyperglycemia as a cardiovascular risk factor

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

The glucagon-like peptides

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

New developments in the incretin concept

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Glucagon-like peptide-1 enhances cardiac L-type Ca2+ currents via activation of the cAMP-dependent protein kinase A pathway

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Improved glycemic control enhances the incretin effect in patients with type 2 diabetes

31 May 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0142-7

GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0142-7

GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0142-7

Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0142-7

Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0142-7

Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0142-7

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0142-7

Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0142-7

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0142-7

Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0142-7

Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0142-7

Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0142-7

Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0142-7

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0142-7

Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0142-7

Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0142-7

A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0142-7

Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Recent trends in cardiovascular complications among men and women with and without diabetes.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216654

Simultaneous GLP-1 and Insulin Administration Acutely Enhances Their Vasodilatory, Antiinflammatory, and Antioxidant Action in Type 2 Diabetes

28 November 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0142-7

Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial

21 January 2018

1 reference

12 December 2020

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure

1 reference

12 December 2020

Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride

1 reference

12 December 2020

Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor

1 reference

12 December 2020

Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor.

1 reference

12 December 2020

Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression

1 reference

12 December 2020

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

1 reference

12 December 2020

Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats

1 reference

12 December 2020

Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury

1 reference

12 December 2020

Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease

1 reference

12 December 2020

NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE

1 reference

12 December 2020

Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting

1 reference

12 December 2020

10.1186/S12933-014-0142-7

Identifiers

DOI

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25338737%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

21 February 2020

1032376861

0 references

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25338737%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25338737%20AND%20SRC:MED&resulttype=core&format=json